SFM
NKGN

Spartan Fund Management’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Spartan Fund Management’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-62,987
Closed -$523K – 249
2023
Q3 		$523K Sell
62,987
-162,874
-72% -$1.66M 0.39% 82
2023
Q2 		$2.33M Buy
225,861
+224,461
+16,033% +$2.3M 1.14% 26
2023
Q1 		$14.2K Buy
+1,400
New +$14.1K 0.01% 225

Other funds holding NKGN

SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.21B AUM 13.69% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
UOC
University of Chicago Chicago, Illinois $420M AUM 42.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Spartan Fund Management's NKGN Position: Q4 2023 in Review

Spartan Fund Management sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q4 2023, closing a stake of 62,987 shares — an estimated $523K sold.

Spartan Fund Management first reported a position in NKGN in Q1 2023 and held it in 3 quarters. The position peaked at $2.33M in Q2 2023. 9 funds tracked by Wall St. Rank hold NKGN as of Q4 2023.

  • Spartan Fund Management reported no remaining NKGen Biotech, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Spartan Fund Management sold 62,987 NKGen Biotech, Inc. Common Stock shares in Q4 2023, an estimated $523K.
  • Spartan Fund Management first reported a position in NKGen Biotech, Inc. Common Stock in Q1 2023 and held it in 3 quarters.
  • Spartan Fund Management's NKGen Biotech, Inc. Common Stock position peaked at $2.33M in Q2 2023.
  • 9 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q4 2023.

Based on Spartan Fund Management's 13F filing for Q4 2023, filed 7 Feb 2024.